Garching/Munich and Münster, Germany  – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the University of Münster today announced updated preliminary results from a Phase 1 clinical trial of investigational candidate, ITM-31 (177Lu-6A10-Fab), an intracavitary targeted radiotherapy, in patients with glioblastoma. These data showed a...

BALA CYNWYD, Pa. — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced it has submitted the first module of its rolling Biologics License Application (BLA) submission to the Food and Drug Administration (FDA) for accelerated approval of nomlabofusp;...

NEW YORK, NY and WALTHAM, Mass. — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (gMG). “Given the impressive Phase 2 MG...